S-8: Securities to be offered to employees in employee benefit plans
Published on January 22, 2026
As filed with the Securities and Exchange Commission on January 22, 2026
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Opus Genetics, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware
|
11-3516358
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification Number.)
|
|
8 Davis Drive
Durham, NC
|
27713
|
|
|
(Address of principal executive offices)
|
(Zip code)
|
|
Ocuphire Pharma, Inc. 2020 Equity Incentive Plan
|
|
(Full title of the plan)
|
|
Dr. George Magrath
Chief Executive Officer
Opus Genetics, Inc.
8 Davis Drive
Durham, NC 27713
(984) 884-6030
|
|
(Name, address, and telephone number, including area code, of agent for service)
|
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions
of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer ☐
|
Accelerated filer ☐
|
|
Non-accelerated filer ☒
|
Smaller reporting company ☒
|
|
Emerging growth company ☐
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
INFORMATION REQUIRED PURSUANT TO GENERAL INSTRUCTION E TO FORM S-8
This Registration Statement on Form S-8 (this “Registration Statement”) is being filed by Opus Genetics, Inc. (the “Registrant”) relating to 3,494,725 shares of its common stock, par value $0.0001 per share
(the “Common Stock”), to be issued pursuant to the Ocuphire Pharma, Inc. 2020 Equity Incentive Plan (the “Plan”). This Registration Statement on Form S-8 hereby incorporates by reference the contents of the Registrant's prior Registration Statements on
Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on November 9, 2020 (Registration No. 333-249978), March 31, 2021 (Registration No. 333-254923), April 5,
2022 (Registration No. 333-264139), April 5, 2023 (Registration No. 333-271150), January 11, 2024 (Registration No. 333-276471) and September
26, 2025 (Registration No. 333-290551) relating to shares of Common Stock issuable under the Plan (the “Prior Registration Statements”). The Prior Registration Statements are currently effective. This Registration Statement relates to securities
of the same class as those to which the Prior Registration Statements relate and is submitted in accordance with General Instruction E of Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the
contents of the Prior Registration Statements are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
All information required by Part I to be contained in the prospectus is omitted from this Registration Statement in accordance with the explanatory note to Part I of Form S-8 and Rule 428 under the
Securities Act of 1933, as amended (the “Securities Act”). Documents containing the information required by Part I of the Registration Statement will be sent or given to Plan participants as specified by Rule 428(b)(1) under the Securities Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
| Item 3. |
Incorporation of Documents By Reference.
|
The following documents filed with the Commission by the Registrant are hereby incorporated by reference in this Registration Statement:
| (a) |
the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 31, 2025 (the “2024 Annual Report”);
|
| (b) |
the Registrant’s Quarterly Reports on Form 10-Q, filed with the Commission on May 15, 2025, August 13, 2025 and November 12, 2025;
|
| (c) |
the Registrant’s Current Reports on Form 8-K, filed with the Commission on January 7, 2025, January 14, 2025, January 23, 2025, January
24, 2025, March 4, 2025, March 20, 2025, March
24, 2025, April 4, 2025, May 1, 2025, June 20,
2025, June 25, 2025, June 26, 2025, July
23, 2025, August 25, 2025, September 2, 2025, September 30, 2025, November 6, 2025, November 6, 2025, and December 19, 2025; and
|
| (d) |
the description of the Registrant’s Common Stock contained in the Registrant’s Form 8-A (File No. 001-34079), as filed with the Commission pursuant to Sections 12(b) and 12(g) of the Securities Exchange Act of
1934, as amended (the “Exchange Act”), on June 7, 2019, including any amendments or reports filed for the
purpose of updating such description, including Exhibit 4.12 to the 2024 Annual Report.
|
All documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, after the date of this Registration Statement and prior to the
filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and
to be a part hereof from the respective dates of filing of such documents (such documents, and the documents enumerated above, being hereinafter referred to as “Incorporated Documents”).
Any statement contained in an Incorporated Document shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other
subsequently filed Incorporated Document modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
Notwithstanding the foregoing, unless specifically stated to the contrary, none of the information disclosed by the Registrant under Items 2.02 or 7.01 of any current report on Form 8-K, including the
related exhibits under Item 9.01, that the Registrant may from time to time furnish to the Commission will be incorporated by reference into, or otherwise included in, this Registration Statement.
| Item 8.1 |
Exhibits.
|
|
Exhibit
Number
|
Description
|
|
Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q, filed with the Commission on August 13, 2024).
|
|
|
Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed with the Commission on
October 22, 2024).
|
|
|
Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on March 20, 2025).
|
|
|
Ocuphire Pharma, Inc. 2020 Equity Incentive Plan (incorporated by reference to Annex D to the Registrant’s Registration Statement on Form S-4, filed with the Commission on July 6, 2020).
|
|
|
Opinion of Sidley Austin LLP.
|
|
|
Consent of Ernst & Young LLP.
|
|
|
Consent of Sidley Austin LLP (included in Exhibit 5.1).
|
|
|
Power of Attorney (included after the signature of the Registrant contained on Signature Page of this Registration Statement).
|
|
|
Filing Fee Table.
|
* Filed herewith.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly
caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Durham, State of North Carolina, on January 22, 2026.
|
OPUS GENETICS, INC.
|
||
|
By:
|
/s/ Dr. George Magrath
|
|
|
Name:
|
Dr. George Magrath
|
|
|
Title:
|
Chief Executive Officer
|
|
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Dr. George Magrath and Robert Gagnon as his or her true and lawful attorneys-in-fact and
agents with full power of substitution, severally, for him in any and all capacities, to sign the Registration Statement on Form S-8 of Opus Genetics, Inc., and any or all amendments (including post-effective amendments thereto), and to file the same,
with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and
necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully
do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.
|
SIGNATURE
|
TITLE
|
DATE
|
||
|
/s/ Dr. George Magrath
|
||||
|
Dr. George Magrath
|
Chief Executive Officer & Director
(Principal Executive Officer)
|
January 22, 2026
|
||
|
/s/ Robert Gagnon
|
||||
|
Robert Gagnon
|
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)
|
January 22, 2026
|
||
|
/s/ Cam Gallagher
|
||||
|
Cam Gallagher
|
Chair of the Board
|
January 22, 2026
|
||
|
/s/ Sean Ainsworth
|
||||
|
Sean Ainsworth
|
Director
|
January 22, 2026
|
||
|
/s/ Dr. Jean Bennett
|
||||
|
Dr. Jean Bennett
|
Director
|
January 22, 2026
|
||
|
/s/ Susan K. Benton
|
||||
|
Susan K. Benton
|
Director
|
January 22, 2026
|
||
|
/s/ Dr. Adrienne Graves
|
||||
|
Dr. Adrienne Graves
|
Director
|
January 22, 2026
|
||
|
/s/ Dr. James S. Manuso
|
||||
|
Dr. James S. Manuso
|
Director
|
January 22, 2026
|
||
|
/s/ Richard J. Rodgers
|
||||
|
Richard J. Rodgers
|
Director
|
January 22, 2026
|
||
|
/s/ Dr. Benjamin R. Yerxa
|
||||
|
Dr. Benjamin R. Yerxa
|
President and Director
|
January 22, 2026
|